glp-1 in body and Anesthesia: Considerations and Cautions for CRNAs GLP-1/glucagon receptor co-agonism for treatment

doi:10.1186/s12978-019-0769-7

Last reviewed: June 19, 2026 Last updated: June 19, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations

As a fellowship-trained shoulder surgeon, I take the science seriously

Depletion of GSH and therapeutic implications The depletion of GSH levels has been demonstrated in aging and multiple chronic degenerative diseases, including neurodegenerative, cardiovascular, pulmonary, immune disorders and cancers (24, 25)

The plan moves forward only when the clinical and fulfillment path makes sense